DSY Dassault Systemes SA

Dassault Systèmes: Declaration of the number of outstanding shares and voting rights as of December 31, 2020

Dassault Systèmes: Declaration of the number of outstanding shares and voting rights as of December 31, 2020

Declaration of the number of outstanding shares and

voting rights as of December 31, 2020

Vélizy-Villacoublay (France) January 8, 2021 – (Euronext Paris: #13065, DSY.PA) reports below the total number of its outstanding shares and voting rights as of December 31, 2020, according to articles 223-16 and 221-3 of the General Regulation of the Autorité des marchés financiers.

                                                                                                                                                   

Number of outstanding shares: 265,136,237

                                                                                  

Number of voting rights*: 397,104,361



*The total number of voting rights is calculated on the basis of the total number of outstanding shares, even if the voting rights attached thereto are suspended, pursuant to Article 223-11 of the General Regulation of the Autorité des marchés financiers relating to the method for calculating the percentages of holdings in shares and in voting rights. We invite our shareholders to refer to this article should they need to declare crossing of thresholds.

Declarations related to crossing of threshold must be sent to:

Dassault Systèmes, Investors Relations Service, 10, rue Marcel Dassault, CS 40501, 78946 Vélizy-Villacoublay Cedex (France). E-mail address:

CONTACTS:

Dassault Systèmes/Investors Relations:                                           

François-José Bordonado/Béatrix Martinez

4

Attachment



EN
08/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dassault Systemes SA

Dassault Systemes Sa: 1 director

A director at Dassault Systemes Sa bought 75,000 shares at 26.282EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

 PRESS RELEASE

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi ...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey  Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration w...

 PRESS RELEASE

Mise à jour : Dassault Systèmes : Medidata étend sa collaboration avec...

Mise à jour : Dassault Systèmes : Medidata étend sa collaboration avec Sanofi pour développer de nouvelles thérapies visant à améliorer le parcours patient Medidata étend sa collaboration avec Sanofi pour développer de nouvelles thérapies visant à améliorer le parcours patient Une collaboration de plus de dix ans renforcée autour des Medidata Experiences, a pour l’objectif d’optimiser les processus et les données cliniques en améliorant la prise en charge des patients. New York, le 23 octobre 2025 – , marque de Dassault Systèmes et leader des solutions numériques pour les essais cliniques...

 PRESS RELEASE

Mise à jour : Dassault Systèmes : Sanofi renforce sa collaboration ave...

Mise à jour : Dassault Systèmes : Sanofi renforce sa collaboration avec Medidata pour accélérer le développement de nouvelles thérapies et améliorer le parcours patient Sanofi renforce sa collaboration avec Medidata pour accélérer le développement de nouvelles thérapies et améliorer le parcours patient Une collaboration de plus de dix ans élargie autour des Medidata Experiences, permettant à Sanofi d’optimiser ses opérations, d’affiner la qualité de ses données et d’améliorer la prise en charge des patients. New York, le 23 octobre 2025 – , marque de Dassault Systèmes et leader des soluti...

 PRESS RELEASE

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi ...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey  Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration w...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch